Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 9, 2026, 11:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 507 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Prevention Clear all
Completed Not applicable Interventional Results available

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

NCT05853900
View directory record Official record
Conditions
Migraine, Episodic Migraine, Headache, Headache, Migraine
Interventions
ReMMi-D Digital Therapeutic
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SEEK: Dissemination and Implementation

NCT03642327
View directory record Official record
Conditions
Child Maltreatment
Interventions
Experimental: Maintenance of Certification (MOC), Independent online training (IND)
Behavioral · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 2 Interventional

A Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine

NCT00158002
View directory record Official record
Conditions
Basilar Migraine
Interventions
Topiramate
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

NCT04464707
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Little Rock, Arkansas • Banning, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing Rectal USPE Measures

NCT02102867
View directory record Official record
Conditions
Microbicide Delivery System Perceptibility and Acceptability
Interventions
Gel, Cream, Liquid
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Open-trial on the Prevention of Chronic Migraines With the CEFALY Device

NCT02342743
View directory record Official record
Conditions
Migraine
Interventions
CEFALY
Device
Lead sponsor
Cefaly Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00003538
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Jun 9, 2026, 11:34 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

NCT03836040
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients

NCT00629447
View directory record Official record
Conditions
Primary Brain Tumor
Interventions
Innohep
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
138
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

NCT00501059
View directory record Official record
Conditions
Moderate Risk of CVD
Interventions
Aspirin (Acetylsalicylic acid, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
55 Years and older
Enrollment
12,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
73
States / cities
Birmingham, Alabama • Graysville, Alabama • Pell City, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Jun 9, 2026, 11:34 PM EDT
Terminated Phase 2 Interventional

Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

NCT05016661
View directory record Official record
Conditions
Migraine
Interventions
ABP-450
Drug
Lead sponsor
AEON Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jun 9, 2026, 11:34 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

NCT06033703
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jun 9, 2026, 11:34 PM EDT
Terminated Phase 2 Interventional Results available

A Study in Migraine Prevention

NCT01184508
View directory record Official record
Conditions
Migraine Headache
Interventions
Placebo, LY2300559
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Phoenix, Arizona • Long Beach, California • Fairfield, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

NCT00002043
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Dapsone
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional Results available

Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients

NCT02647658
View directory record Official record
Conditions
Low Back Pain
Interventions
Guideline Based Care plus Psychologically Informed Physical Therapy, Guideline Based Care (GBC)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jun 9, 2026, 11:34 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.

NCT01251263
View directory record Official record
Conditions
Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
Interventions
Estradiol or Placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2010 · Synced Jun 9, 2026, 11:34 PM EDT
Terminated Phase 4 Interventional Results available

Therapy for Migraine Prevention in Children 6-11 Years of Age

NCT04050293
View directory record Official record
Conditions
Migraine Disorders, Headache Disorders
Interventions
SPN-538, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 9, 2026, 11:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Nudges for Diabetes Prevention (BEGIN) Trial in Primary Care

NCT04869917
View directory record Official record
Conditions
PreDiabetes
Interventions
Decision Aid intervention, Text Messaging intervention, Usual Care
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional

Clinical Study Examining Use of an Over-the-Counter Supplement for the Prevention of Menstrually-Associated Migraine Headache

NCT00203255
View directory record Official record
Conditions
Migraine Headache
Interventions
Soy Isoflavones
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Jun 9, 2026, 11:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Presyncope (Syncope) Prevention Study

NCT04772755
View directory record Official record
Conditions
Syncope, Vasovagal
Interventions
Buzzy® and Electronic Game
Device
Lead sponsor
Duke University
Other
Eligibility
10 Years to 14 Years
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Jun 9, 2026, 11:34 PM EDT